Capital International Inc. CA purchased a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 55,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,467,000.
Several other institutional investors have also recently modified their holdings of the company. Utah Retirement Systems raised its holdings in Juno Therapeutics by 1.8% during the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after acquiring an additional 200 shares in the last quarter. State of Wisconsin Investment Board increased its position in Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Aperio Group LLC increased its position in Juno Therapeutics by 4.2% during the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,194 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Juno Therapeutics by 9.5% during the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 1,328 shares during the last quarter. Institutional investors own 70.37% of the company’s stock.
In related news, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Company insiders own 15.08% of the company’s stock.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at $44.68 on Friday. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% compared to the same quarter last year. During the same period last year, the business posted ($0.57) EPS. analysts anticipate that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current fiscal year.
Several equities analysts have recently commented on the company. Maxim Group set a $56.00 target price on Juno Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Raymond James Financial reissued a “buy” rating on shares of Juno Therapeutics in a research report on Monday, December 11th. Wells Fargo & Company downgraded Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, Cowen restated a “buy” rating on shares of Juno Therapeutics in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.48.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.